Published in Am J Pathol on March 01, 2006
Nuclear factor-kappa B signaling in skeletal muscle atrophy. J Mol Med (Berl) (2008) 1.86
N-Acetylcysteine ameliorates skeletal muscle pathophysiology in mdx mice. J Physiol (2008) 1.60
Skeletal muscle NADPH oxidase is increased and triggers stretch-induced damage in the mdx mouse. PLoS One (2010) 1.29
L-arginine decreases inflammation and modulates the nuclear factor-kappaB/matrix metalloproteinase cascade in mdx muscle fibers. Am J Pathol (2008) 1.25
Reactive oxygen species in skeletal muscle signaling. J Signal Transduct (2011) 1.23
Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies. Am J Pathol (2010) 1.14
Peptide-based inhibition of NF-κB rescues diaphragm muscle contractile dysfunction in a murine model of Duchenne muscular dystrophy. Mol Med (2011) 1.09
Inhibitory control over Ca(2+) sparks via mechanosensitive channels is disrupted in dystrophin deficient muscle but restored by mini-dystrophin expression. PLoS One (2008) 1.08
Microarchitecture is severely compromised but motor protein function is preserved in dystrophic mdx skeletal muscle. Biophys J (2010) 1.08
Wasting mechanisms in muscular dystrophy. Int J Biochem Cell Biol (2013) 1.07
Modulation of p38 mitogen-activated protein kinase cascade and metalloproteinase activity in diaphragm muscle in response to free radical scavenger administration in dystrophin-deficient Mdx mice. Am J Pathol (2007) 1.07
Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy. Br J Pharmacol (2008) 1.07
Subcutaneous injection, from birth, of epigallocatechin-3-gallate, a component of green tea, limits the onset of muscular dystrophy in mdx mice: a quantitative histological, immunohistochemical and electrophysiological study. Histochem Cell Biol (2008) 1.02
Green tea extract decreases muscle pathology and NF-kappaB immunostaining in regenerating muscle fibers of mdx mice. Clin Nutr (2009) 0.99
Enalapril treatment discloses an early role of angiotensin II in inflammation- and oxidative stress-related muscle damage in dystrophic mdx mice. Pharmacol Res (2011) 0.96
Protein-DNA array-based identification of transcription factor activities differentially regulated in skeletal muscle of normal and dystrophin-deficient mdx mice. Mol Cell Biochem (2008) 0.93
Systemic delivery of NEMO binding domain/IKKγ inhibitory peptide to young mdx mice improves dystrophic skeletal muscle histopathology. Neurobiol Dis (2011) 0.92
L-type Ca2+ channel function is linked to dystrophin expression in mammalian muscle. PLoS One (2008) 0.92
Therapeutic targeting of signaling pathways in muscular dystrophy. J Mol Med (Berl) (2009) 0.90
Increased catalase expression improves muscle function in mdx mice. Exp Physiol (2010) 0.90
Activation of NF-kappaB pathway in Duchenne muscular dystrophy: relation to age. Acta Myol (2011) 0.89
Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials. ILAR J (2014) 0.88
Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy. Physiol Rev (2016) 0.85
The role of oxidative stress in skeletal muscle injury and regeneration: focus on antioxidant enzymes. J Muscle Res Cell Motil (2016) 0.85
RhoA mediates defective stem cell function and heterotopic ossification in dystrophic muscle of mice. FASEB J (2013) 0.83
Selective modulation through the glucocorticoid receptor ameliorates muscle pathology in mdx mice. J Pathol (2013) 0.82
Role of inflammation and oxidative stress mediators in gliomas. Cancers (Basel) (2010) 0.78
NBD delivery improves the disease phenotype of the golden retriever model of Duchenne muscular dystrophy. Skelet Muscle (2014) 0.78
Delayed cardiomyopathy in dystrophin deficient mdx mice relies on intrinsic glutathione resource. Am J Pathol (2010) 0.78
Proteomic analysis of brain protein expression levels in NF-kappabeta p50 -/- homozygous knockout mice. Brain Res (2008) 0.77
Flavocoxid, a nutraceutical approach to blunt inflammatory conditions. Mediators Inflamm (2014) 0.77
Effect of nuclear factor κB inhibition on serotype 9 adeno-associated viral (AAV9) minidystrophin gene transfer to the mdx mouse. Mol Med (2012) 0.75
Improvement of endurance of DMD animal model using natural polyphenols. Biomed Res Int (2015) 0.75
D-Amino Acid Substitution of Peptide-Mediated NF-κB Suppression in mdx Mice Preserves Therapeutic Benefit in Skeletal Muscle, but Causes Kidney Toxicity. Mol Med (2015) 0.75
Effect of the IL-1 Receptor Antagonist Kineret® on Disease Phenotype in mdx Mice. PLoS One (2016) 0.75
Membrane organization of the dystrophin-glycoprotein complex. Cell (1991) 6.64
Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature (1992) 6.37
The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature (1991) 5.40
Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature (1990) 4.23
The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol (2000) 4.11
Nuclear factor-kappaB: its role in health and disease. J Mol Med (Berl) (2004) 4.01
Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci U S A (2001) 3.06
The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J Biol Chem (1999) 3.04
The role of nuclear factor-kappa B in cytokine gene regulation. Am J Respir Cell Mol Biol (1997) 2.89
Glycoprotein complex anchoring dystrophin to sarcolemma. J Biochem (1990) 2.51
Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy. FASEB J (2003) 2.12
Muscular dystrophy in the mdx mouse: histopathology of the soleus and extensor digitorum longus muscles. J Neurol Sci (1987) 2.03
Three mouse models of muscular dystrophy: the natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin alpha2-deficient mice. Neuromuscul Disord (2001) 1.97
Tumor necrosis factor-alpha and muscle wasting: a cellular perspective. Respir Res (2001) 1.88
Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med (1998) 1.86
Activation of nuclear factor-kappaB in inflammatory myopathies and Duchenne muscular dystrophy. Neurology (2003) 1.74
Pre-clinical screening of drugs using the mdx mouse. Neuromuscul Disord (2000) 1.58
Expression of matrix metalloproteinases 2 and 9 in regenerating skeletal muscle: a study in experimentally injured and mdx muscles. Dev Biol (1999) 1.58
NF kappa B and AP-1 mediate transcriptional responses to oxidative stress in skeletal muscle cells. Free Radic Biol Med (2001) 1.51
Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB J (2004) 1.44
Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol (1995) 1.42
Evidence of oxidative stress in mdx mouse muscle: studies of the pre-necrotic state. J Neurol Sci (1998) 1.37
Muscle cells from mdx mice have an increased susceptibility to oxidative stress. Neuromuscul Disord (1998) 1.34
Insulin-like growth factor-II, phosphatidylinositol 3-kinase, nuclear factor-kappaB and inducible nitric-oxide synthase define a common myogenic signaling pathway. J Biol Chem (1999) 1.28
Systemic administration of the NF-kappaB inhibitor curcumin stimulates muscle regeneration after traumatic injury. Am J Physiol (1999) 1.27
The role of nuclear factor kappa B in the pathogenesis of pulmonary diseases: implications for therapy. Am J Respir Med (2003) 1.27
How does dystrophin deficiency lead to muscle degeneration?--evidence from the mdx mouse. Neuromuscul Disord (1995) 1.18
Green tea extract decreases muscle necrosis in mdx mice and protects against reactive oxygen species. Am J Clin Nutr (2002) 1.15
Study of gene regulation by NF-kappa B and AP-1 in response to reactive oxygen intermediates. Methods (1997) 1.13
Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin Cancer Res (1998) 1.10
The IKK/NF-kappaB pathway. Crit Care Med (2002) 1.08
Early onset of lipofuscin accumulation in dystrophin-deficient skeletal muscles of DMD patients and mdx mice. J Mol Histol (2004) 1.00
IRFI 042, a novel dual vitamin E-like antioxidant, inhibits activation of nuclear factor-kappaB and reduces the inflammatory response in myocardial ischemia-reperfusion injury. Cardiovasc Res (2000) 0.98
Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice. Neuromuscul Disord (2002) 0.96
Patients with dystrophinopathy show evidence of increased oxidative stress. Free Radic Biol Med (2003) 0.96
Oxidative stress as a potential pathogenic mechanism in an animal model of Duchenne muscular dystrophy. Neuromuscul Disord (1997) 0.95
The NF-kappaB pathway as a potential target for autoimmune disease therapy. Curr Pharm Des (2004) 0.95
Haemostatic abnormalities, cardiac involvement and serum tumor necrosis factor levels in X-linked dystrophic patients. Thromb Haemost (1999) 0.94
Oxidative damage to muscle protein in Duchenne muscular dystrophy. Neuroreport (1996) 0.94
Inhibition of nuclear factor-kappaB activation by IRFI 042, protects against endotoxin-induced shock. Cardiovasc Res (2002) 0.92
Oxidative stress and muscular dystrophy. Chem Biol Interact (1989) 0.91
Modulation of IL-1 beta gene expression by lipid peroxidation inhibition after kainic acid-induced rat brain injury. Exp Neurol (2004) 0.88
Elevated plasma levels of tumor necrosis factor in chronic heart failure with cachexia. Int J Cardiol (1997) 0.86
Potential oxyradical damage and energy status in individual muscle fibres from degenerating muscle diseases. Neuromuscul Disord (1992) 0.83
Free radicals: a potential pathogenic mechanism in inherited muscular dystrophy. Life Sci (1986) 0.81
[Clinical significance of measurement of circulating tumor necrosis factor alpha]. Rinsho Byori (2001) 0.78
Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol (2011) 2.44
North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord (2010) 2.14
Efferent vagal fibre stimulation blunts nuclear factor-kappaB activation and protects against hypovolemic hemorrhagic shock. Circulation (2003) 2.03
Activation of an efferent cholinergic pathway produces strong protection against myocardial ischemia/reperfusion injury in rats. Crit Care Med (2005) 1.96
Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. Ann Intern Med (2007) 1.76
The effect of PDRN, an adenosine receptor A2A agonist, on the healing of chronic diabetic foot ulcers: results of a clinical trial. J Clin Endocrinol Metab (2014) 1.75
Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. J Bone Miner Res (2002) 1.69
miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. J Neurooncol (2009) 1.68
Both early and delayed treatment with melanocortin 4 receptor-stimulating melanocortins produces neuroprotection in cerebral ischemia. Endocrinology (2005) 1.63
Microsurgical arterovenous loops and biological templates: a novel in vivo chamber for tissue engineering. Microsurgery (2007) 1.54
Effect of recombinant adeno-associated virus vector-mediated vascular endothelial growth factor gene transfer on wound healing after burn injury. Crit Care Med (2003) 1.50
Protective effects of melanocortins on short-term changes in a rat model of traumatic brain injury*. Crit Care Med (2012) 1.45
Effectiveness of skeletal scintigraphy in transthyretin-related amyloidosis. Int J Cardiol (2013) 1.43
Melanocortin 4 receptor stimulation decreases pancreatitis severity in rats by activation of the cholinergic anti-inflammatory pathway. Crit Care Med (2011) 1.43
Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice. Exp Neurol (2006) 1.39
Vascular endothelial growth factor induces brain erythropoietin expression? Funct Neurol (2006) 1.38
Beta-arrestin 2 negatively regulates sepsis-induced inflammation. Immunology (2010) 1.33
Anticonvulsant activity of androsterone and etiocholanolone. Epilepsia (2005) 1.30
Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats. Arthritis Res Ther (2003) 1.29
Recombinant human erythropoietin stimulates angiogenesis and wound healing in the genetically diabetic mouse. Diabetes (2004) 1.29
Effects of the phytoestrogen genistein on some predictors of cardiovascular risk in osteopenic, postmenopausal women: a two-year randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab (2007) 1.18
VEGF overexpression via adeno-associated virus gene transfer promotes skeletal muscle regeneration and enhances muscle function in mdx mice. FASEB J (2007) 1.18
Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy. Neurology (2012) 1.17
Adrenocorticotropin reverses hemorrhagic shock in anesthetized rats through the rapid activation of a vagal anti-inflammatory pathway. Cardiovasc Res (2004) 1.15
Sleep disorders in children with Attention-Deficit/Hyperactivity Disorder (ADHD) recorded overnight by video-polysomnography. Sleep Med (2009) 1.13
Nuclear factor-kappaB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas. Cancer (2008) 1.13
Effect of genistein on endothelial function in postmenopausal women: a randomized, double-blind, controlled study. Am J Med (2003) 1.12
Recombinant human erythropoietin improves angiogenesis and wound healing in experimental burn wounds. Crit Care Med (2006) 1.12
Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci (Lond) (2005) 1.12
Attenuated cerulein-induced pancreatitis in nuclear factor-kappaB-deficient mice. Lab Invest (2003) 1.10
Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study. J Clin Endocrinol Metab (2008) 1.10
Polydeoxyribonucleotide stimulates angiogenesis and wound healing in the genetically diabetic mouse. Wound Repair Regen (2008) 1.08
The effect of the phytoestrogen genistein on plasma nitric oxide concentrations, endothelin-1 levels and endothelium dependent vasodilation in postmenopausal women. Atherosclerosis (2002) 1.08
Motor function-muscle strength relationship in spinal muscular atrophy. Muscle Nerve (2004) 1.07